Made Therapeutics, Inc. announced a brokered private placement of subscription receipts at a price per subscription receipt to be determined in the context of the market for targeted gross proceeds of up to CAD 15,000,000 on February 2, 2021. Pursuant to their terms, upon the conditions to conversion being met prior to June 30, 2021, including the receipt of necessary approvals to complete the transaction, the receipts will be converted into units of company, each of which will be comprised of one share and one-half of one common share purchase warrant, with each, warrant being exercisable for one share at an exercise price per share to be determined in the context of the market for a period of 24 months following the closing.